Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Reed

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Alzheimer'S & Dementia (New York, N. Y.)|October 27, 2018
Hearing treatment for reducing cognitive decline: Design and methods of the Aging and Cognitive Health Evaluation in Elders randomized controlled trialJennifer A Deal, Adele M Goman, Marilyn S Albert, et al.
Gynecologic Oncology|April 22, 2019
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumorMartin Gore, Allan Hackshaw, William E Brady, et al.
The Lancet. Oncology|October 28, 2017
Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trialPiero Ferolla, Maria Pia Brizzi, Tim Meyer, et al.
BJC Reports|November 8, 2024
Radiomics and outcome prediction to antiangiogenic treatment in advanced gastroenteropancreatic neuroendocrine tumours: findings from the phase II TALENT trialMarta Ligero, Jorge Hernando, Eric Delgado, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2021
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)Jaume Capdevila, Nicola Fazio, Carlos Lopez, et al.
Lancet (London, England)|October 17, 2024
Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trialMary McCormack, Gemma Eminowicz, Dolores Gallardo, et al.
Cancers|January 30, 2021
GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future DirectionsRiccardo Di Fiore, Sherif Suleiman, Bridget Ellul, et al.
The New England Journal of Medicine|January 12, 2017
Phase 3 Trial of <sup>177</sup>Lu-Dotatate for Midgut Neuroendocrine TumorsJonathan Strosberg, Ghassan El-Haddad, Edward Wolin, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 4, 2020
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with <sup>177</sup>Lu-Dotatate: an analysis of the NETTER-1 studyJonathan Strosberg, Pamela L Kunz, Andrew Hendifar, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Alzheimer'S & Dementia (New York, N. Y.)|October 27, 2018
Hearing treatment for reducing cognitive decline: Design and methods of the Aging and Cognitive Health Evaluation in Elders randomized controlled trialJennifer A Deal, Adele M Goman, Marilyn S Albert, et al.
Gynecologic Oncology|April 22, 2019
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumorMartin Gore, Allan Hackshaw, William E Brady, et al.
The Lancet. Oncology|October 28, 2017
Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trialPiero Ferolla, Maria Pia Brizzi, Tim Meyer, et al.
BJC Reports|November 8, 2024
Radiomics and outcome prediction to antiangiogenic treatment in advanced gastroenteropancreatic neuroendocrine tumours: findings from the phase II TALENT trialMarta Ligero, Jorge Hernando, Eric Delgado, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2021
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)Jaume Capdevila, Nicola Fazio, Carlos Lopez, et al.
Lancet (London, England)|October 17, 2024
Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trialMary McCormack, Gemma Eminowicz, Dolores Gallardo, et al.
Cancers|January 30, 2021
GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future DirectionsRiccardo Di Fiore, Sherif Suleiman, Bridget Ellul, et al.
The New England Journal of Medicine|January 12, 2017
Phase 3 Trial of <sup>177</sup>Lu-Dotatate for Midgut Neuroendocrine TumorsJonathan Strosberg, Ghassan El-Haddad, Edward Wolin, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 4, 2020
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with <sup>177</sup>Lu-Dotatate: an analysis of the NETTER-1 studyJonathan Strosberg, Pamela L Kunz, Andrew Hendifar, et al.
Pageof 7